# EDGAR Filing Document

**Accession Number:** 0001643918
**File Stem:** 0001214659-25-014284
**Filing Date:** 2025-9
**Character Count:** 2577
**Document Hash:** f04f8b80fc300fcb1237d9fe9e6d3e02
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-25-014284.hdr.sgml**: 20260128

**ACCESSION NUMBER**: 0001214659-25-014284

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250929

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biodexa Pharmaceuticals Plc
- **CENTRAL INDEX KEY:** 0001643918
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 CASPIAN POINT
- **STREET 2:** CASPIAN WAY
- **CITY:** CARDIFF
- **PROVINCE COUNTRY:** X0
- **ZIP:** CF10 4DQ
- **BUSINESS PHONE:** 44 (0)1235 888300

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 CASPIAN POINT
- **STREET 2:** CASPIAN WAY
- **CITY:** CARDIFF
- **PROVINCE COUNTRY:** X0
- **ZIP:** CF10 4DQ

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Midatech Pharma Plc
- **DATE OF NAME CHANGE:** 20150602

**Biodexa Pharmaceuticals PLC**

**1 Caspian Point**

**Caspian Way**

**Cardiff, CF10 4DQ**

**United Kingdom**

September 29, 2025

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E. Washington, D.C. 20549

Attention: Jessica Dickerson

---

| | |
|:---|:---|
| **Re:** | **Biodexa Pharmaceuticals PLC<br> Registration Statement on Form F-3<br> File No. 333-290554 (the "Registration Statement")<br> <u>Acceleration Request</u>** |

---

Ladies and Gentlemen:

In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Biodexa Pharmaceuticals PLC (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Tuesday, September 30, 2025, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please contact Jason S. McCaffrey of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (617) 348-4416 with any questions regarding this request.

---

| |
|:---|
| Very truly yours, |
| Biodexa Pharmaceuticals PLC |
| /s/ Stephen Stamp |
| Stephen Stamp<br> Chief Executive Officer |

---

cc: *<u>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</u>*<br> Jason S. McCaffrey, Esq.